Unique ID issued by UMIN | UMIN000024063 |
---|---|
Receipt number | R000025503 |
Scientific Title | Effect of Feru-guard 100M on the progression prevention of mild cognitive impairment associated |
Date of disclosure of the study information | 2016/09/15 |
Last modified on | 2019/03/08 08:48:00 |
Effect of Feru-guard 100M on the progression prevention of mild cognitive impairment associated
Effect of Feru-guard
Effect of Feru-guard 100M on the progression prevention of mild cognitive impairment associated
Effect of Feru-guard
Japan |
Mild Cognitive Impairment
Neurology | Geriatrics | Psychiatry |
Others
NO
To investigate the effect of the Feru-Guard100M(ferulic acid supplement) on cognitive function of MCI.
Efficacy
Clinical Gloval Impression
Criteria: Changes of cognitive impairment in comparison with before intervention.
1. Remarkable improvement of MCI
2. Improvement of MCI
3. No change
4. Hypofunction of cognitive
Term: 24weeks, 48weeks
ADAS-jcog
MMSE
RBMT
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Test food:capsule(ferulic acid, garden angelica)
Administration period:48weeks
Test food:capsule(not contained ferulic acid, garden angelica)
Administration period:48weeks
49 | years-old | < |
Not applicable |
Male and Female
1. stuff forget there is complained of, that is supported by family and friends if possible
2. The general cognitive function is normal
3. housework and ADL, including the work it is generally normal
4. it is not a dementia
5.MMSE-J score more than 24 points
6.GDS-S-J is less than or equal to 5 points
7.ADAS-Jcog. Is less than or equal to 10 points or more three-point
8. MCIS score until the zero point below 49.8 points
9. Age is less than 85 years of age or 65 years of age
1. Patients who have merged the neurodegenerative disease which presents a dementia-like symptoms, or there is a suspicion
Parkinson's disease, Huntington's disease, Down's syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, cortical basal degeneration, etc.
2. patient suspected failure in cognitive function due to causes of the following
Vascular dementia, metabolic diseases (hypothyroidism, vitamin B12 hypothyroidism, folic acid deficiency, etc.), head trauma, normal pressure hydrocephalus
3. Patients with delirium due to drug addiction
Patients 4. there is a history of the following disease onset before Alcoholism, stroke, depression, manic state, schizophrenia
5. malignant neoplasm, patients with acute inflammatory disease
6. Patients have experience taking Feru-guard in the past
7. Patients have medication anti-dementia drugs
8. CDR-J 1 or more
9. HbA1c 8.0 or higher
10. If clear metabolic syndrome
11. Other
12. If the principal investigator or researcher has determined that improper participation in the present study
140
1st name | |
Middle name | |
Last name | Tomokatsu Hori |
SHIN-YURIGAOKA General Hospital
Cranial nerve surgery
255 Hurusawa Aso-ku Kawasaki Kanagawa
044-322-9991
tomokatsu.hori@mt.strins.or.jp
1st name | |
Middle name | |
Last name | Shinya Yamamoto |
Glovia Co., Ltd.
Department of clinical research
2-9-6-7F Shinkawa Chuo-ku Tokyo
03-6228-3376
yamamoto@glovia.co.jp
Glovia Co., Ltd.
Glovia Co., Ltd.
Profit organization
NO
2016 | Year | 09 | Month | 15 | Day |
Partially published
Completed
2016 | Year | 08 | Month | 01 | Day |
2016 | Year | 09 | Month | 01 | Day |
2018 | Year | 12 | Month | 31 | Day |
2019 | Year | 02 | Month | 28 | Day |
2019 | Year | 02 | Month | 28 | Day |
2019 | Year | 03 | Month | 31 | Day |
2016 | Year | 09 | Month | 15 | Day |
2019 | Year | 03 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025503
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |